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ADDITIONAL CRYSTALLOGRAPHIC INFORMATION 
 
CCDC 1575834 (3), 1443595 (12), 1575835 (13), 1575836 (14a), 1575837 (15) and 1575838 (41) 
contain the crystallographic data of the complexes shown in the paper; CCDC 1575459 (4), 1575460 
(8) and 1575461 (17) contain the crystallographic data of the complexes shown below (SI only): 
 









Figure S3. Structure of imine 17 formed by azobenzene metathesis 
 
General. All reactions were carried out under an Ar atmosphere in flame-dried glassware unless 
stated otherwise. Solvents were purified by distillation over the indicated drying agents and were 
transferred under Ar: toluene (Na/K, stored over molecular sieves), 1,2-dichloroethane (CaH2), CH2Cl2 
(CaH2), CD2Cl2 (dried and stored over molecular sieves, degassed three times by the freeze-pump-
thaw method), methanol (Mg), pentane (Na/K, degassed three times by the freeze-pump-thaw 
method), fluorobenzene (CaH2); pyridine was dried by an absorption solvent purification system 
based on molecular sieves. Flash chromatography: Merck Geduran® Si 60 (40–63 μm). NMR: Spectra 
were recorded at room temperature unless stated otherwise, on Bruker AV 400s and AV 500as 
spectrometers in the indicated solvents; chemical shifts (δ) are given in ppm relative to TMS (15N 
spectra were referenced externally to MeNO2), coupling constants (J) in Hz. The solvent signals were 
used as references (CDCl3: δC = 77.16 ppm; residual CHCl3 in CDCl3: δH = 7.26 ppm; CD2Cl2: 
δC = 53.84 ppm; residual CHDCl2 in CD2Cl2: δH = 5.32 ppm); 
1H and 13C assignments were established 
using NOESY, HSQC and HMBC experiments; numbering schemes as shown in the Inserts. IR: Perkin-
Elmer Spectrum One spectrometer, wavenumbers (ṽ) in cm−1. MS: EI: Finnigan MAT 8400 (70 eV), ESI: 
Thermo Scientific LTQ-FT or Thermo Scientific Exactive, GC-EI: Thermo Scientific Trace GC Ultra with a 
Thermo Scientific ISQ spectrometer, accurate mass determinations: Finnigan MAT 95, Thermo 
Scientific LTQ FT, or Thermo Scientific Exactive. 
A self-made set-up was used for reactions carried out under irradiation with light emitted by blue 
LEDs. Two LED strips were secured to the inside of a plastic container (12 cm×12 cm×18 cm), of which 
the end was cut open (Figure S4). The LED strips were purchased from Conrad Electronic SE 
(www.conrad.de, SKU: 150536) and possess the following characteristics: wave length λ = 470 nm, 
luminous intensity IV = 250 mcd, angle of radiation 110°, 48 LEDs per strip (3 per unit), strip length 




   
Figure S4: Self-made LED array. 
 
Substrates. Unless stated otherwise, all commercially available compounds (ABCR, Acros, Sigma-
Aldrich, TCI) were used as received. [Cp*RhCl2]2 and [Cp*Rh(MeCN)3](SbF6)2 were purchased from 
STREM. [Cp*IrCl2]2, [Cp*IrI2]2 and [IrCl(cod)]2 were purchased from Sigma-Aldrich and used as 
received. 
The following compounds were prepared according to the cited literature: [Cp*RhI2]2,
1 [Cp*RhBr2]2,
2 
bis(4-methoxyphenyl)diazomethane (5a),3 bis(4-(dimethylamino)phenyl)diazomethane (5b),4 methyl 
2-diazo-2-(4-methoxyphenyl)acetate (6a),5 methyl 2-diazo-2-phenylacetate (6b),5 methyl 4-(1-diazo-
2-ethoxy-2-oxoethyl)benzoate (6c),6 9-diazo-9H-fluorene,7 (Z)-1,2-diphenyldiazene (Z-16),8 (E)-1,2-
bis(4-methoxyphenyl)diazene,9 (E)-1,2-bis(4-fluorophenyl)diazene,9 (E)-1,2-bis(4-(trifluoro-
methyl)phenyl)diazene,10  (E)-1,2-bis(3,5-dimethylphenyl)diazene,9,11 (E)-1,2-di-p-tolyldiazene,9 
dioctyl 4,4'-(diazene-1,2-diyl)(E)-dibenzoate,12  (E)-1,2-bis(2,6-dimethylphenyl)diazene,13 (E)-1,2-bis(3-
methoxyphenyl)diazene,9,10 (E)-1-(p-tolyl)-2-(4-(trifluoromethyl)phenyl)diazene,14  (E)-1,2-di-o-tolyl-
diazene,9   (E)-1,1'-(diazene-1,2-diylbis(3,1-phenylene))bis(ethan-1-one),9,15 (E)-1,2-bis(4-azido-
phenyl)diazene16. 
 
Dioctyl 3,3'-(diazene-1,2-diyl)(E)-dibenzoate. n-Octanol (1.1 mL, 6.99 mmol) and pyridine (1.0 mL, 
12.36 mmol) were added to a solution of (E)-3,3'-
(diazene-1,2-diyl)dibenzoyl chloride (897 mg, 
2.92 mmol)17 in toluene (30 mL) and the resulting 
mixture was stirred at reflux temperature for 3 h. The mixture was poured onto an ice-water 
(150 mL) and the aqueous phase was extracted with toluene (3 × 60 mL). The combined organic 
layers were washed with HCl (2 M, 60 mL) and deionized water (2 × 40 mL), dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified by flash chromatography (silica, 
hexane/EtOAc, 20:1) to give the title compound as a bright orange solid (1.28 g, 89%). M.p.: 45–
S-5 
 
46 °C; 1H NMR (400 MHz, CDCl3): δ = 8.60 (t, J = 1.7 Hz, 2 H), 8.18 (dt, J = 7.8 Hz, J = 1.4 Hz, 2 H), 8.12 
(ddd, J = 7.9 Hz, J = 2.0 Hz, J = 1.2 Hz, 2 H), 7.61 (t, J = 7.9 Hz, 2 H), 4.38 (t, J = 6.7 Hz, 4 H), 1.86–1.76 
(m, 4 H), 1.53–1.22 (m, 20 H), 0.88 (t, J = 6.9 Hz, 6 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 166.2, 152.6, 
132.2, 132.0, 129.4, 126.7, 124.7, 65.7, 31.9, 29.4, 29.3, 28.9, 26.2, 22.8, 14.2; IR (film): 𝜈 = 2949, 
2920, 2853, 1718, 1467, 1441, 1285, 1269, 1210, 1153, 1103, 969, 924, 754, 688; MS (EI, %): m/z = 
495 (33), 494 [M]+ (100), 365 (23), 261 (4), 253 (5), 123 (7), 105 (22), 91 (18), 69 (12); HRMS (ESI+): 
m/z: calculated for C30H42N2O4Na [M+Na]
+: 517.30368, found: 517.30345. 
(E)-1,2-Bis(4-(prop-1-yn-1-yl)phenyl)diazene. A mixture of 4-(prop-1-yn-1-yl)aniline (401 mg, 
3.06 mmol),18 CuBr (32.6 mg, 0.23 mmol) and pyridine 
(0.06 mL, 0.74 mmol) in toluene (12 mL) was stirred under air 
at 60 °C. After 7 h the solvent was evaporated and the crude 
material was purified by flash chromatography (silica, 
hexane/EtOAc, 30:120:1) to give the title compound as an 
orange solid (355 mg, 90%). M.p.: 194-195 °C; 1H NMR (400 MHz, CDCl3): δ = 7.89–7.78 (m, 4 H), 
7.56–7. 47(m, 4 H), 2.09 (s, 6 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 151.5, 132.4, 127.1, 123.0, 89.0, 
79.8, 4.7; IR (film): 𝜈 = 2913, 2251, 2212, 1594, 1494, 1404, 1153, 1100, 846, 558; MS (GC-EI, %): m/z 
= 258 [M]+ (21), 143 (20), 130 (2), 115 (100), 103 (1), 89 (20), 77 (2), 65 (13), 63 (11); HRMS (ESI+): 
m/z: calculated for C18H15N2 [M+H]
+: 259.12297, found: 259.12296. 
 
Structural and Mechanistic Investigations 
Representative Procedure for the Preparation of Iridium Carbene Complexes. Dichloro[2-methoxy-
1-(4-methoxyphenyl)-2-oxoethylidene](η5-pentamethylcyclopentadienyl)iridium 
(13). A solution of the diazo compound 6a (10.4 mg, 0.050 mmol) in 
fluorobenzene (0.5 mL) was added dropwise to a solution of [Cp*IrCl2]2 (20 mg, 
0.025 mmol) in CH2Cl2 (1 mL) at 0 °C. Crystals suitable for X-ray diffraction were 
grown by layering this solution with cold toluene (1 mL) and hexane (5 mL) at 
−20 °C. 
For the preparation of NMR samples, a solution of the diazo compound in CD2Cl2 (0.5 mL) was added 
dropwise to an ice-cold solution of the iridium complex in CD2Cl2 (1.0 mL). The solution was stirred 
under cooling in an ice bath for 5 min before it was transferred into an NMR tube. 1H NMR (500 MHz, 
CD2Cl2): δ = 8.16 (s br, 2 H, H3, H3’), 7.11–6.96 (m, 2 H, H4, H4’), 3.98 (s, 3 H, H6), 3.93 (s, 3 H, H8), 
1.52 (s, 15 H, H10); 13C{1H} NMR (126 MHz, CD2Cl2): δ = 275.9 (C1), 182.8 (C7), 169.1 (C5), 150.0 (C2), 
116.4 (C4, C4’), 97.7 (C9), 57.1 (C6), 51.0 (C8), 8.3 (C10); one signal (C3, C3’) was not detected 
(probably very broad); HRMS (ESI+): m/z: calcd. for C20H25O3ClIr [M−Cl]
+: 541.11196; found: 
541.11229. 




dienyl)iridium (14a). Prepared according to the representative procedure 
from diazo compound 6c (12.5 mg, 0.050 mmol) and [Cp*IrCl2]2 (19 mg, 
0.017 mmol). 1H NMR (500 MHz, CD2Cl2, 243 K): δ = 8.16–8.06 (m, 4 H), 4.45 
(s br, 2 H), 3.91 (s, 3 H), 1.46 (s, 15 H), 1.34 (t, J = 7.2 Hz, 3 H); 13C{1H} NMR 
(126 MHz, CD2Cl2, 243 K): δ = 275.4 (C1), 185.0 (C8), 166.4 (C6), 160.4 (2), 
133.9 (C5), 131.1 (C4, C4’), 130.8 (s br, C3, C3’), 101.6 (C11), 61.1 (C9), 53.0 
(C7), 14.4 (C10), 8.9 (C12); HRMS (ESI+): m/z: calcd. for C22H27O4ClIr [M−Cl]
+: 
583.12253; found: 583.12226. 
Diiodo[2-ethoxy-1-(4-(methoxycarbonyl)phenyl)-2-oxoethylidene](η5-pentamethylcyclopenta-
dienyl)iridium (14b). Prepared according to the representative procedure 
from diazo compound 6c (8.5 mg, 0.034 mmol) and [Cp*IrI2]2 (20 mg, 
0.017 mmol). 1H NMR (500 MHz, CD2Cl2, 243 K): δ = 8.14–8.10 (m, 2 H, H3, 
H3’), 8.00–7.96 (m, 2 H, H4, H4’), 4.42 (q, J = 7.2 Hz, 2 H, H9), 3.90 (s, 3 H, H7), 
1.70 (s, 15 H, H12), 1.32 (t, J = 7.2 Hz, 3 H, H10); 13C{1H} NMR (126 MHz, 
CD2Cl2, 243 K): δ = 272.6 (C1), 188.6 (C8), 166.6 (C6), 162.8 (C2), 133.9 (C5), 
130.9 (C4, C4’), 129.4 (C3, C3’), 102.4 (C11), 61.0 (C9), 53.0 (C7), 14.1 (C10), 
10.4 (C12); HRMS (ESI+): m/z: calcd. for C22H27O4IIr [M−I]
+: 675.05815; found: 675.05852. 
Chloro[(1,2,5,6-η)-1,5-cyclooctadiene][2-methoxy-1-(4-methoxyphenyl)-2-oxoethylidene]iridium 
(15). Prepared according to the representative procedure from diazo 
compound 6a (12.3 mg, 0.060 mmol) and [IrCl(cod)]2 (20 mg, 0.030 mmol).  
1H 
NMR (500 MHz, CD2Cl2): δ = 8.23 (s br, 2 H, ), 7.02–6.94 (m, 2 H), 5.41 (s br, 
2 H), 3.99 (s, 3 H), 3.90 (s br, 3 H), 3.78 (s br, 1 H), 3.45 (s br, 1 H), 2.63–2.06 
(m br, 8 H); 13C{1H} NMR (126 MHz, CD2Cl2): δ = 288.1 (C1), 182.0 (C8), 165.8 
(C5), 148.9 (C2), 138.9 (s br, C3, C7), 117.1 (C4, C6), 102.6 (s br, C15), 102.4 (s 
br, C16), 64.5 (s brC11, C12), 56.7 (C10), 51.8 (C9), 34.5 (s br, C13), 33.5 (s br, 




(12). Prepared according to the representative procedure from diazo 
compound 5b (18.9 mg, 0.067 mmol) and [Cp*RhCl2]2 (21.5 mg, 
0.035 mmol). 1H NMR (400 MHz, CD2Cl2, 243 K): δ = 7.60–7.55 (m, 4 H, H3), 
6.64–6.60 (m, 4 H, H4), 3.13 (s, 12 H, H6), 1.35 (s, 15 H, H8); 13C{1H} NMR 
(126 MHz, CD2Cl2, 243 K): δ = 291.8 (d, J = 34.3 Hz, C1), 154.5 (C5), 144.2 
(C2), 137.8 (C3), 109.1 (C4), 98.2 (d, J = 6.3 Hz, C7), 40.3 (C6), 9.2 (C8); 15N 
NMR (50 MHz, CD2Cl2, 243 K): δ = −308.6 (the 
15N resonance were observed by 1H/15N-HMBC 
spectroscopy); HRMS (ESI+): m/z: calcd. for C27H35ClN2Rh [M−Cl]




Phenylbenzamidine (33.2 mg, 0.169 mmol), [Cp*RhCl2]2 (49.5 mg, 
0.080 mmol) and NaOAc (41.0 mg, 0.500 mmol) in toluene (3 mL) were 
stirred overnight at reflux temperature. The volatiles were removed in vacuo 
and the residue was extracted with CH2Cl2 (5 × 3 mL). The solution was 
concentrated until a precipitate formed, which was collected by filtration 
and dried in vacuo to give 4 as an orange powder (47 mg, 63%). Crystals suitable for X-ray diffraction 
were grown by slow diffusion of n-pentane into a solution of 4 in CH2Cl2. M.p.: >250 °C; 
1H NMR 
(400 MHz, CD2Cl2): δ = 7.72 (dd, J = 7.6 Hz, J = 0.9 Hz, 1 H, H4), 7.51 (s br, 2 H, H11, H15), 7.42 (t, 
J = 7.8 Hz, 2 H, H12, H14), 7.24 (dd, J = 7.7 Hz, J = 1.2 Hz, 1 H, H7), 7.23–7.17 (m, 1 H, H13), 7.13 (td, 
J = 7.4 Hz, J = 1.0 Hz, 1 H, H5), 6.80 (t, J = 7.5 Hz, 1 H, H6), 5.26 (s br, 2 H, NH2), 1.32 (s, 15 H, H2); 
13C{1H} NMR (100 MHz, CD2Cl2): δ = 179.3 (d, J = 32.2 Hz, C3), 164.5 (d, J = 2.9 Hz, C9), 147.8 (C10), 
141.3 (C8), 136.9 (C4), 130.6 (C5), 129.7 (s br, C12, C14), 125.8 (C13), 125.0 (s br, C11, C15), 124.4 
(C7), 122.5 (C6), 95.5 (d, J = 6.5 Hz, C1), 8.8 (C2); IR (solid):  𝜈 = 3420, 3299, 3240, 3214, 3191, 3173, 
1631, 1588, 1488, 1418, 738, 702; HRMS (EI): m/z: calcd. For C23H26N2ClRh [M]
+: 468.08325; found: 
468.08340. 
(Acetonitrile) [2-(N’-phenylcarbamimidoyl-κN’)phenyl](η5-pentamethylcyclopentadienyl)rhodium 
hexafluoroantimonat (2). [Cp*Rh(MeCN)3](SbF6)2 (51.1 mg, 
0.061 mmol), NaOAc (50.3 mg, 0.613 mmol) and N-
phenylbenzamidine (12.7 mg, 0.065 mmol) in MeCN (5 mL) were 
stirred at reflux temperature for 1 h. The volatiles were removed in 
vacuo. The residue was extracted with CH2Cl2 (4 × 2 mL) and filtered 
over Celite. The volatiles were removed in vacuo and the residue was washed with Et2O (2 × 0.5 mL). 
Upon drying in vacuo the residue solidified and complex 2 was obtained as a red orange powder 
(35 mg, 80%). 1H NMR (400 MHz, CD2Cl2): δ = 7.82 (dd, J = 7.6 Hz, J = 0.6 Hz, 1 H, H4), 7.60–7.53 (m, 
2 H, H12, H12’), 7.40 (td, J = 7.4 Hz, J = 1.3 Hz, 1 H, H5), 7.37–7.31 (m, 2 H, H7, H13), 7.27–7.17 (m, 
3 H, H6, H11), 5.67 (s br, 2 H, NH2), 2.27 (s, 3 H, H15), 1.40 (s, 15 H, H2); 
13C{1H} NMR (100 MHz, 
CD2Cl2): δ = 174.5 (d, J = 30.2 Hz, C3), 165.7 (d, J = 2.9 Hz, C9), 146.4 (C10), 141.1 (C8), 136.7 (C4), 
130.7 (C12, C12’), 127.1 (C13), 124.9 (C7), 124.4 (C11, C11’), 124.2 (C6), 122.6 (s br, C14), 97.9 (d, 
J = 6.5 Hz, C1), 8.8 (C2), 3.9 (C15); IR (solid):  𝜈 = 3488, 3396, 3058, 2975, 2912, 1629, 1586, 1546, 





antimonat (3). Prepared according to the representative procedure 
from diazo compound 5a (7.7 mg, 0.030 mmol) and complex 2 
(20.5 mg, 0.029 mmol) at −20 °C. 1H NMR (400 MHz, CD2Cl2, 273 K): δ = 
7.89–7.81 (m, 1 H, H3), 7.49–7.38 (m, 3 H, H1, H2, H6), 7.34–7.27 (m, 
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2 H, H10, H10’), 7.26–7.16 (m, 1 H, H20), 7.19–7.12 (m, 3 H, H11, H14, H14’), 7.06 (dd, J = 8.0 Hz, 
J = 2.8 Hz, 1 H, H20’), 6.82 (d, J = 8.9 Hz, 2 H, H15, H15’), 6.70 (dd, J = 8.0 Hz, J = 2.5 Hz, 1 H, H19’), 
6.65 (dd, J = 9.2 Hz, J = 2.4 Hz, 1 H, H19), 6.02 (s br, 2 H, H9, H9’), 5.72 (s br, 1 H, NH2), 5.23 (s br, 1 H, 
NH2), 4.00 (s, 3 H, H22), 3.82 (s, 3 H, H17), 0.98 (s, 15 H, H24); 
13C{1H} NMR (100 MHz, CD2Cl2, 273 K): 
δ = 163.1 (C21), 159.8 (C7), 158.9 (C16), 148.2 (C8), 143.0 (C4), 138.6 (C13), 133.3 (C6), 132.5 (C11), 
131.7 (C1), 131.2 (C19), 130.0 (C10, C10‘), 128.9 (C3), 127.4 (C2), 126.7 (C14, C14‘), 126.0 (C20), 
124.3 (C9, C9‘), 113.1 (C15, C15‘), 109.9 (C20‘), 106.7 (C18), 105.6 (C19‘), 99.5 (d, J = 7.2 Hz, C23), 
96.7 (d, J = 6.3 Hz, C5), 71.4 (d, J = 14.3 Hz, C12), 56.4 (C22), 55.6 (C17), 8.6 (C24). HRMS (ESI+): m/z: 
calcd. for C38H40N2O2Rh [M−SbF6]
+: 659.21393; found: 659.21414. 
In solution complex 3 is in equilibrium with the isomeric complex 3’. The ratio 3:3’ was determined to 
be ≈2.5:1. 1H NMR (400 MHz, CD2Cl2, 273 K): δ = 7.73 (ddd, J = 8.4 Hz, 
J = 6.7 Hz, J = 1.4 Hz, 1 H, H2), 7.65 (dd, J = 9.0 Hz, J = 1.4 Hz, 1 H, H6), 
7.52–7.46 (m, 2 H, H14, H14’), 7.49–7.38 (m, 1 H, H11), 7.34–7.27 (m, 
2 H, H10, H10’), 7.24–7.15 (m, 1 H, H1), 7.19–7.12 (m, 1 H, H3), 7.08 (s 
br, 1 H, C7–NH–C8), 7.05–6.98 (m, 2 H, H9, H9’), 6.89–6.81 (m, 3 H, H15, 
H15’, H19), 6.57 (dd, J = 8.4 Hz, J = 2.5 Hz, 1 H, H19’), 6.34 (dd, J = 8.4 Hz, 
J = 2.8 Hz, 1 H, H20), 6.30 (dd, J = 8.6 Hz, J = 2.8 Hz, 1 H, H20’), 6.12 (s br, 
1 H, C7–NH), 3.77 (s, 3 H, H17), 3.42 (s, 3 H, H22), 1.39 (s, 15 H, H24); 
13C{1H} NMR (100 MHz, CD2Cl2, 273 K): δ = 165.8 (C8), 158.9 (C7), 158.0 (C16), 157.4 (C21), 138.0 
(C13), 136.6 (C18), 134.4 (C6), 133.0 (C19), 132.4 (C14, C14‘), 132.3 (C11), 129.5 (C3), 128.7 (C10, 
C10’, C19‘), 127.1 (C2), 126.6 (C9, C9‘), 126.1 (C1), 115.9 (C4), 114.2 (C20), 113.5 (C15, C15‘), 112.4 
(C20’), 97.6 (d, J = 6.9 Hz, C23), 91.8 (d, J = 4.2 Hz, C5), 84.1 (d, J = 13.2 Hz, C12), 55.4 (C17), 55.2 
(C22), 8.8 (C24). 
Stoichiometric NMR Experiments. A cold (0 °C) solution of diazo compound 6a (9.1 mg, 0.044 mmol) 
in degassed CD2Cl2 (0.5 mL) was added dropwise to a cold (0 °C) solution of [Cp*RhI2]2 (21.6 mg, 
0.022 mmol) in CD2Cl2 (1 mL). The mixture was stirred for 10 min whilst cooling in an ice bath before 
it was cooled to −78 °C and solid (Z)-16 (8.5 mg, 0.047 mmol) was added in one portion. After 5 min 
this mixture was transferred to a precooled (−78 °C) NMR tube. 
Methyl 3-(4-methoxyphenyl)-1,2-diphenyldiaziridine-3-carboxylate (41). A cold (0 °C) solution of 
the diazo compound 6a (9.4 mg, 0.046 mmol) in degassed CD2Cl2 (0.5 mL) 
was added dropwise to an ice-cold solution of [Cp*RhI2]2 (22.4 mg, 
0.023 mmol) in CD2Cl2 (1 mL) and the resulting mixture was stirred for 
15 min whilst cooling in an ice bath. The mixture was cooled to −78 °C 
before solid (Z)-16 (8.8 mg, 0.048 mmol) was added in one portion and the 
resulting mixture was stored at −40 °C overnight. The mixture was layered 
with precooled (−40 °C) and carefully degassed n-pentane (1.5 mL) and stored at the same 
temperature, which resulted in precipitation of a red solid material. The mother liquor was 
transferred into another precooled (−40 °C) Schlenk tube, layered with precooled (−40 °C) n-pentane 
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(2 mL), and slowly cooled to −78 °C to give the title compound in the form of small colorless crystals 
suitable for X-ray diffraction. The material analyzed as follows: 1H NMR (500 MHz, CD2Cl2, 233 K): δ = 
7.35–7.29 (m, 2 H, H22, H22’), 7.29–7.25 (m, 2 H, H3, H3’), 7.25–7.21 (m, 2 H, H21, H21’), 7.19–7.13 
(m, 1 H, H23), 7.13–7.07 (m, 2 H, H12, H12’), 6.98–6.92 (m, 3 H, H11, H11’, H13), 6.76–6.70 (m, 2 H, 
H4, H4’), 3.69 (s, 3 H, H6), 3.45 (s, 3 H, H8); 13C{1H} NMR (125 MHz, CD2Cl2, 233 K): δ = 166.4 (C7), 
159.9 (C5), 148.3 (C20), 147.1 (C10), 129.9 (C3, C3’), 128.6 (C22, C22’), 128.2 (C12, C12’), 125.0 (C23), 
124.1 (C13), 122.5 (C2), 120.7 (C11, C11’), 120.0 (C21, C21’), 113.1 (C4, C4’), 73.4 (C1), 55.2 (C6), 52.9 
(C8); 15N NMR (50 Hz, CD2Cl2, 233 K): δ = −252.2 (N1), −263.2 (the 
15N resonances were observed by 
1H/15N-HMBC spectroscopy). HRMS (ESI+): m/z: calculated for C22H21N2O3 [M+H]
+: 361.15467, found: 
361.15439. 
 
Substrate and Catalyst Screening 
Representative Procedure for the Iridium Catalyzed Insertion of Diazo Compounds into O–H Bonds. 
Methyl 2-methoxy-2-(4-methoxyphenyl)acetate (9a, X = OMe). The diazo derivative 6a (20.0 mg, 
0.097 mmol) was added in portions to a solution of [Cp*IrCl2]2 (1.0 mg, 
1.3 µmol) and methanol (39 µL, 0.970 mmol) in pentane (3 mL). After 
consumption of the starting material, as indicated by TLC, the reaction 
mixture was concentrated in vacuo. The residue was purified by flash 
chromatography (silica, hexane/EtOAc, 10:15:1) to give the title compound as a light yellow oil 
(15 mg, 74%). The spectral data matched the previously reported values.19 1H NMR (400 MHz, CDCl3): 
δ = 7.38–7.32 (m, 2 H), 6.92–6.86 (m, 2 H), 4.72 (s, 1 H), 3.80 (s, 3 H), 3.71 (s, 3 H), 3.37 (s, 3 H); 
13C{1H} NMR (100 MHz, CDCl3): δ = 171.5, 160.1, 128.7, 128.3, 114.2, 82.2, 57.2, 55.4, 52.4. 
Methyl 4-(2-ethoxy-1-methoxy-2-oxoethyl)benzoate (9b, X = COOEt). Prepared analogously in the 
form of a light orange oil (48 mg, 90%).The spectral data matched the 
previously reported values.20 1H NMR (400 MHz, CDCl3): δ = 8.06–8.01 (m, 
2 H), 7.56–7.51 (m, 2 H), 4.81 (s, 1 H), 4.24–4.19 (m, 2 H), 3.91 (s, 3 H), 3.43 
(s, 3 H), 1.21 (t, J = 7.1 Hz, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 170.2, 
166.9, 141.4, 130.6, 130.0, 127.2, 82.4, 61.7, 57.7, 52.3, 14.2. 
Procedures for the Iridium Catalyzed Cyclopropanation of 4-Methoxystyrene with Diazo 
Compounds. 
Methyl (E)-1,2-bis(4-methoxyphenyl)cyclopropane-1-carboxylate (7a). The diazo compound 6a 
(20.0 mg, 0.097 mmol) was added in one portion to a solution of 
[Cp*IrCl2]2 (1.0 mg, 1.3 µmol) and 4-methoxystyrene (120 mg, 
0.894 mmol) in CH2Cl2 (3 mL) and the resulting mixture was stirred at 
40 °C. After consumption of the starting material, as indicated by TLC, 
the mixture was concentrated in vacuo. The residue was purified by flash chromatography (silica, 
hexane/EtOAc, 5:1) to give the title compound as a colorless liquid (19 mg, 63%). The spectral data 
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matched the previously reported values.21 1H NMR (400 MHz, CDCl3): δ = 6.96–6.91 (m, 2 H), 6.71–
6.68 (m, 2 H), 6.68–6.66 (m, 2 H), 6.64–6.59 (m, 2 H), 3.73 (s, 3 H), 3.71 (s, 3 H), 3.65 (s, 3 H), 3.02 (dd, 
J = 9.4 Hz, J = 7.3 Hz, 1 H), 2.10 (dd, J = 9.4 Hz, J = 4.8 Hz, 1 H), 1.75 (dd, J = 7.3 Hz, J = 4.8 Hz, 1 H); 
13C{1H} NMR (100 MHz, CDCl3): δ = 174.9, 158.5, 158.2, 133.1, 129.2, 128.6, 127.1, 113.3 (2 C), 55.2 
(2 C), 52.7, 36.4, 32.9, 21.0. 
Methyl 4-((E)-1-(ethoxycarbonyl)-2-(4-methoxyphenyl)cyclopropyl)benzoate (7b). A solution of the 
diazo compound 6c (49.3 mg, 0.199 mmol) in CH2Cl2 (2 mL) was 
added via syringe pump over the course of 1 h to a solution of 
[Cp*IrI2]2 (2.3 mg, 2.0 µmol) and 4-methoxystyrene (0.26 mL, 
1.96 mmol) in CH2Cl2 (1 mL). After consumption of the starting 
material (TLC), the mixture was concentrated in vacuo. The residue was purified by flash 
chromatography (silica, hexane/EtOAc, 5:15:2) to give the title compound as a light orange oil 
(41 mg, 58%). 1H NMR (400 MHz, CDCl3): δ = 7.83–7.78 (m, 2 H), 7.13–7.08 (m, 2 H), 6.71–6.67 (m, 
2 H), 6.62–6.57 (m, 2 H), 4.20–4.06 (m, 2 H), 3.86 (s, 3 H), 3.69 (s, 3 H), 3.09 (dd, J = 9.4 Hz, J = 7.3 Hz, 
1 H), 2.13 (dd, J = 9.4 Hz, J = 5.0 Hz, 1 H), 1.84 (dd, J = 7.3 Hz, J = 5.0 Hz, 1 H), 1.16 (t, J = 7.1 Hz, 3 H); 
13C{1H} NMR (100 MHz, CDCl3): δ = 173.3, 167.2, 158.4, 140.7, 132.1, 129.1, 129.1, 128.8, 127.9, 
113.5, 61.5, 55.3, 52.2, 37.2, 32.9, 20.1, 14.3; IR (liquid): 𝜈 = 2982, 2953, 2907, 2837, 1711, 1611, 
1514, 1436, 1275, 1173, 159, 1103, 1020, 831, 706; MS (EI, %): m/z = 534 [M]+ (100), 325 (26), 308 
(61), 281 (66, 279 (29), 265 (11), 249 (35), 221 (31), 207 (10), 189 (13), 178 (19), 165 (21), 145 (11), 
137 (12), 121 (13), 115 (13); HRMS (ESI+): m/z: calculated for C21H22O5Na [M+Na]
+: 377.13594, found: 
377.13562. 
Representative Procedure for the Rhodium Catalyzed Epoxidation Reactions. Methyl (Z)-2,3-
diphenyloxirane-2-carboxylate (Table 2, entry 1). A solution of the diazo 
compound 6b (67.3 mg, 0.382 mmol) in CH2Cl2 (2 mL) was added via syringe pump 
over the course of 1 h to a solution of benzaldehyde (26.0 mg, 0.250 mmol) and 
[Cp*RhI2]2 (2.8 mg, 1.2 µmol) in CH2Cl2 (1 mL). After consumption of the starting material, as 
indicated by TLC, the mixture was concentrated in vacuo. The residue was purified by flash 
chromatography (silica, hexane/EtOAc, 20:110:1) to give the title compound as a colorless oil 
(39 mg, 63%). The spectral data matched the previously reported values.22 1H NMR (400 MHz, CDCl3): 
δ = 7.67–7.63 (m, 2 H), 7.45–7.33 (m, 8 H), 4.16 (s, 1 H), 3.55 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): 
δ = 167.2, 134.8, 133.9, 129.0, 128.8, 128.7, 128.5, 126.3, 126.1, 67.2, 66.0, 52.4. 
The following compounds were prepared analogously: 
Methyl (Z)-3-(4-methoxyphenyl)-2-phenyloxirane-2-carboxylate (Table 2, entry 4). Colorless oil 
(62 mg, 96%). The spectral data matched the previously reported values.23 
1H NMR (400 MHz, CDCl3): δ = 7.66–7.61 (m, 2 H), 7.43–7.35 (m, 3 H), 7.34–
7.29 (m, 2 H), 6.92–6.87 (m, 2 H), 4.10 (s, 1 H), 3.82 (s, 3 H), 3.58 (s, 3 H); 
13C{1H} NMR (100 MHz, CDCl3): δ = 167.4, 160.0, 134.9, 128.9, 128.7, 127.4, 
126.3, 125.9, 114.0, 67.2, 65.9, 55.4, 52.4. 
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Methyl (Z)-2,3-bis(4-methoxyphenyl)oxirane-2-carboxylate (Table 2, entry 5). Colorless liquid 
(65 mg, 83%). The spectral data matched the previously reported 
values.24 Crystals suitable for X-ray diffraction were grown by slow 
diffusion of hexane into a solution in EtOAc at 5 °C. 1H NMR (400 MHz, 
CDCl3): δ = 7.57–7.52 (m, 2 H), 7.34–7.28 (m, 2 H), 6.95–6.91 (m, 2 H), 
6.91–6.86 (m, 2 H), 4.09 (s, 1 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.57 (s, 
3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 191.0, 167.6, 160.1, 159.9, 127.7, 127.4, 126.9, 125.9, 114.1, 
113.9, 67.0, 65.8, 55.5, 55.4, 52.3. 
Ethyl (Z)-3-(4-(methoxycarbonyl)phenyl)-2-phenyloxirane-2-carboxylate (Table 2, entry 6). Colorless 
oil (69 mg, 85%). 1H NMR (400 MHz, CDCl3): δ = 8.08–8.02 (m, 2 H), 7.67–
7.61 (m, 2 H), 7.51–7.46 (m, 2 H), 7.45–7.39 (m, 3 H), 4.19 (s, 1 H), 3.93 (s, 
3 H), 3.54 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 166.9, 166.8, 138.9, 
134.4, 130.6, 129.8, 129.2, 128.8, 126.3, 126.2, 67.3, 65.4, 52.5, 52.4; IR 
(liquid): 𝜈 = 3063, 3032, 3001, 2953, 1717, 1613, 1435, 1274, 1216, 1193, 1167, 1101, 757, 738, 696; 
MS (EI, %): m/z = 312 [M]+ (1), 284 (2), 281 (3), 253 (1), 225 (<1), 221 (<1), 194 (1), 193 (1), 179 (100), 
165 (4), 148 (4), 133 (2), 120 (1), 105 (17), 89 (3), 77 (7), 63 (1); HRMS (ESI+): m/z: calculated for 
C18H16O5Na [M+Na]
+: 335.08899, found: 335.08869. 
Methyl (Z)-2-phenyl-3-((E)-styryl)oxirane-2-carboxylate (Table 2, entry 7). Colorless oil (58 mg, 
88%). The spectral data matched the previously reported values.25 1H NMR 
(400 MHz, CDCl3): δ = 7.62–7.58 (m, 2 H), 7.43–7.27 (m, 8 H), 6.90 (d, 
J = 16.0 Hz, 1 H), 6.09 (dd, J = 16.0 Hz, J = 7.9 Hz, 1 H), 3.82 (s, 3 H), 3.73 (dd, 
J = 7.9 Hz, J = 0.6 Hz, 1 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 168.3, 137.5, 135.9, 134.9, 128.9, 128.7, 
128.6, 126.9, 126.7, 122.0, 65.9, 65.6, 52.9. 
Methyl (Z)-3-((E)-but-1-en-1-yl)-2-phenyloxirane-2-carboxylate (Table 2, entry 8). Colorless liquid 
(64 mg, 99%). 1H NMR (400 MHz, CDCl3): δ = 7.60–7.53 (m, 2 H), 7.41–7.30 
(m, 3 H), 6.11 (dt, J = 15.5 Hz, J = 6.4 Hz, 1 H), 5.33 (ddt, J = 15.5 Hz, 
J = 8.1 Hz, J = 1.6 Hz, 1 H), 3.81 (s, 3 H), 3.53 (d, J = 8.1 Hz, 1 H), 2.19–2.08 (m, 2 H), 1.02 (t, J = 7.5 Hz, 
3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 168.5, 142.1, 135.2, 128.7, 128.5, 126.7, 122.0, 65.8, 65.2, 
52.7, 25.7, 13.2; IR (liquid): 𝜈 = 2964, 1736, 1435, 1302, 1279, 1200, 1112, 966, 753, 697, 640; MS 
(GC-EI, %): m/z = 232 [M]+ (<1), 216 (1), 187 (4), 173 (8), 157 (6), 155 (7), 145 (25), 129 (15), 117 (12), 
115 (16), 105 (51), 99 (100), 91 (15), 77 (42), 67 (24); HRMS (ESI+): m/z: calculated for C14H16O3Na 





Metathesis of Azobenzene Derivatives 
Representative Procedure for the Rhodium Catalyzed Metathesis between Diazo Compounds and 
Azoarenes Performed at Ambient Temperature. Methyl (Z)-2-phenyl-2-
(phenylimino)acetate (17). A solution of the diazo compound 6b (113.2 mg, 
0.643 mmol) in toluene (2 mL) was added via syringe pump over the course of 2 h to a 
solution of azobenzene 16 (44.8 mg, 0.250 mmol) and [Cp*RhI2]2 (2.3 mg, 2.3 µmol) in toluene (3 mL) 
during constant irradiation of the mixture with the light emitted by blue LEDs (Figure S5). After 
consumption of the starting material, as indicated by TLC, the mixture was concentrated in vacuo. 
The residue was purified by flash chromatography (silica, hexane/EtOAc, 20:1 + 1% Et3N) to give the 
title compound as an orange oil (107 mg, mixture of two geometric isomers (95:5), 91%). The spectral 
data of the major isomer matched the previously reported values.26 Crystals suitable for X-ray 
diffraction were grown by storing a saturated solution in n-pentane in a fridge. 1H NMR (400 MHz, 
CDCl3): δ = 7.90–7.85 (m, 2 H), 7.56–7.44 (m, 3 H), 7.37–7.31 (m, 2 H), 7.17–7.11 (m, 1 H), 6.99–6.94 
(m, 2 H), 3.64 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 165.6, 160.1, 150.2, 134.0, 132.0, 129.0, 
128.9, 128.1, 125.1, 119.6, 52.0. 
 
 
Figure S5: Experimental set-up for the rhodium catalyzed metathesis between diazo compounds and azoarenes 
performed at ambient temperature: Schlenk flask with septum in the center, syringe pump (in green) with 
syringe in the back, self-made LED array (see Figure S4) wrapped in aluminum foil, and argon supply (black 
tubing). 
The following compounds were prepared analogously: 
Methyl (Z)-2-((4-fluorophenyl)imino)-2-phenylacetate (21). Yellow oil (119 mg, mixture of two 
geometric isomers (94:6), 91%). The spectral data of the major isomer are given. 1H 
NMR (400 MHz, CDCl3): δ = 7.88–7.84 (m, 2 H), 7.56–7.50 (m, 1 H), 7.50–7.44 (m, 
2 H), 7.07–7.00 (m, 2 H), 6.97–6.90 (m, 2 H), 3.67 (s); 13C{1H} NMR (100 MHz, 
CDCl3): δ = 165.6, 160.6, 160.5 (d, 
1JCF = 243.8 Hz),146.3 (d, 
4JCF = 2.8 Hz), 133.8, 
132.1, 128.9, 128.1, 121.3 (d, 3JCF = 8.1 Hz), 115.8 (d, 
2JCF = 22.5 Hz), 52.1; 
19F{1H}-NMR (282 MHz, 
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CDCl3): δ = −118.4; IR (liquid): 𝜈 = 3066, 3031, 2953, 1732, 1499, 1229, 1214, 1192, 1170, 1009, 844, 
769, 689; MS (EI, %): m/z = 257 [M]+ (12), 240 (2), 199 (13), 198 (100), 181 (1), 151 (1.03), 104 (), 103 
(1), 95 (14), 91 (5), 77 (6), 75 (7); HRMS (ESI+): m/z: calculated for C15H12NO2F [M+H]
+: 258.09248, 
found: 258.09232. 
Methyl (Z)-2-phenyl-2-(p-tolylimino)acetate (18). Orange oil (124 mg, mixture of two geometric 
isomers (94:6), 97%). The spectral data of the major isomer are given. 1H NMR 
(400 MHz, CDCl3): δ = 7.90–7.84 (m, 2 H), 7.55–7.43 (m, 3 H), 7.17–7.11 (m, 2 H), 
6.92–6.87 (m, 2 H), 3.68 (s, 3 H), 2.34 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 
165.9, 159.7, 147.6, 134.8, 134.1, 131.8, 129.6, 128.8, 128.0, 119.7, 52.0, 21.1; IR 
(liquid): 𝜈 = 3027, 2952, 2923, 1732, 1624, 1504, 1449, 1433, 1301, 1225, 1194, 1166, 1009, 908, 838, 
729; MS (GC-EI, %): m/z = 253 [M]+ (8), 195 (16), 194 (100), 165 (1), 152 (<1), 116 (1), 103 (3), 97 (2), 
91 (36), 77 (5), 65 (30), 63 (5), 51 (5), 39 (8); HRMS (ESI+): m/z: calculated for C16H16NO2 [M+H]
+: 
254.11755, found: 254.11727. 
Methyl (Z)-2-((3,5-dimethylphenyl)imino)-2-phenylacetate (26). Orange-yellow oil (130 mg, mixture 
of two geometric isomers (94:6), 95%). The spectral data of the major isomer are 
given. 1H NMR (400 MHz, CDCl3): δ = 7.89–7.83 (m, 2 H), 7.55–7.43 (m, 3 H), 6.81–
6.77 (m, 1 H), 6.63–6.58 (m, 2 H), 3.68 (s, 3 H), 2.31 (s, 6 H); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 165.8, 159.5, 150.1, 138.7, 134.1, 131.8, 128.8, 128.1, 126.9, 
117.4, 51.9, 21.4; IR (liquid): 𝜈 =2950, 2917, 1732, 1603, 1588, 1449, 1432, 1317, 1280, 1208, 1142, 
1025, 848, 687; MS (GC-EI, %): m/z = 267 [M]+ (10), 209 (16), 208 (100), 193 (1), 166 (<1), 105 (15), 
103 (11), 97 (5), 79( 13), 77 (16), 65 (2), 51 (2); HRMS (ESI+): m/z: calculated for C17H18NO2 [M+H]
+: 
268.13320, found: 268.13299. 
Methyl (Z)-2-((3-methoxyphenyl)imino)-2-phenylacetate (24). Yellow oil (135 mg, mixture of two 
geometric isomers (98:2), 99%). The spectral data of the major isomer are given. 
1H NMR (400 MHz, CDCl3): δ = 7.90–7.84 (m, 2 H), 7.55–7.50 (m, 1 H), 7.50–7.44 
(m, 2 H), 7.26–7.20 (m, 1 H), 6.71 (ddd, 3J = 8.4 Hz, 4J = 2.4 Hz, 4J = 1.0 Hz, 1 H), 
7.25–7.20 (m, 2 H), 3.80 (s, 3 H), 3.67 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 
165.6, 160.2, 160.1, 151.5, 133.9, 132.0, 129.9, 128.9, 128.1, 111.7, 111.3, 105.4, 55.4, 52.1; IR 
(liquid): 𝜈 = 3064, 3003, 2952, 2835, 1731, 1592, 1579, 1480, 1432, 1210, 1139, 1009, 776, 688; MS 
(GC-EI, %): m/z = 269 [M]+ (11), 211 (15), 210 (100), 195 (2), 167 (2), 107 (10), 105 (5), 92 (20), 77 
(24), 64 (11), 51 (2); HRMS (ESI+/−): m/z: calculated for C16H16NO3 [M+H
+]+: 270.11247, found: 
270.11198. 
Methyl (Z)-2-phenyl-2-(o-tolylimino)acetate (23). Yellow oil (109 mg, one isomer, 85%). 1H NMR 
(400 MHz, CDCl3): δ = 7.94–7.89 (m, 2 H), 7.54–7.45 (m, 3 H), 7.22–7.18 (m, 1 H), 
7.16–7.10 (m, 1 H), 7.05 (td, J = 7.4 Hz, J = 1.2 Hz, 1 H), 6.74–6.70 (m, 1 H), 3.61 (s, 
3 H), 2.22 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 165.5, 159.5, 149.1, 133.9, 
131.9, 130.3, 129.3, 128.9, 128.1, 126.3, 125.0, 117.5, 51.9, 18.1; IR (liquid): 𝜈 = 3064, 
3025, 2951, 1733, 1629, 1596, 1578, 1484, 1449, 1433, 1304, 1229, 1203, 1171, 1111, 1009, 754, 
S-14 
 
689; MS (GC-EI, %): m/z = 253 [M]+ (13), 195 (15), 194 (100), 167 (6), 165 (3), 152 (1), 116 (4), 103 (3), 
91 (40), 89 (9), 77 (4), 65 (32), 51 (4); HRMS (ESI+): m/z: calculated for C16H16NO2 [M+H]
+: 254.11755, 
found: 254.11744. 
Octyl (Z)-3-((2-methoxy-2-oxo-1-phenylethylidene)amino)benzoate (25). Yellow oil (169 mg, one 
isomer, 86%). 1H NMR (400 MHz, CDCl3): δ = 7.91–7.86 (m, 2 H), 7.84 (ddd, 
J = 7.8 Hz, J = 1.5 Hz, J = 1.2 Hz, 1 H), 7.68–7.64 (m, 1 H), 7.57–7.51 (m, 
1 H), 7.51–7.45 (m, 2 H), 7.41 (td, J = 7.8 Hz, J = 0.3 Hz, 1 H), 7.15 (ddd, 
J = 7.8 Hz, J = 2.2 Hz, J = 1.1 Hz, 1 H), 4.31 (t, J = 6.7 Hz, 2 H), 3.66 (s, 3 H), 
1.81–1.71 (m, 2 H), 1.49–1.39 (m, 2 H), 1.39–1.20 (m, 8 H), 0.88 (t, J = 6.8 Hz, 3 H); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 166.4, 165.2, 160.9, 150.2, 133.7, 132.2, 131.5, 129.1, 128.9, 128.2, 126.3, 
124.1, 120.8, 65.4, 52.1, 31.9, 29.4, 29.3, 28.8, 26.2, 22.8, 14.2; IR (liquid): 𝜈 = 2953, 2926, 2855, 
1736, 1717, 1625, 1580, 1450, 1433, 1266, 1171, 1103, 1011, 757, 688; MS (EI, %): m/z = 396 (2), 395 
[M]+ (7), 337 (24), 336 (100), 266 (3), 224 (15), 179 (4), 65 (1); HRMS (ESI+): m/z: calculated for 
C24H30NO4 [M+H]
+: 396.21693, found: 396.21668. 
Methyl (Z)-2-((4-methoxyphenyl)imino)-2-phenylacetate (19). Yellow solid (103 mg, mixture of two 
geometric isomers (93:7), 77%). The spectral data of the major isomer matched 
the previously reported values.27 1H NMR (400 MHz, CDCl3): δ = 7.89–7.83 (m, 
2 H), 7.54–7.42 (m, 3 H), 7.00–6.94 (m, 2 H), 6.92–6.85 (m, 2 H), 3.81 (s, 3 H), 
3.70 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 166.3, 159.3, 157.5, 143.3, 
134.3, 131.7, 128.8, 128.0, 121.3, 114.3, 55.6, 52.1. 
Methyl (Z)-2-(4-methoxyphenyl)-2-(phenylimino)acetate (31). Yellow oil (130 mg, one isomer, 97%). 
1H NMR (400 MHz, CD2Cl2): δ = 7.85–7.80 (m, 2 H), 7.35–7.29 (m, 2 H), 7.15–
7.09 (m, 1 H), 7.00–6.93 (m, 2 H), 3.88 (s, 3 H), 3.63 (s, 3 H); 13C{1H} NMR 
(100 MHz, CD2Cl2): δ = 165.9, 163.1, 159.6, 150.8, 130.1, 129.3, 126.9, 125.1, 
120.0, 114.5, 55.9, 52.1; IR (liquid): 𝜈 = 2953, 2839, 1735, 1602, 1591, 1513, 1259, 1164, 1016; MS 
(GC-EI, %): m/z =269 [M]+ (9), 211 (15), 210 (100), 195 (5), 167 (9), 133 (6), 103 (3), 90 (5), 77 (55), 63 
(4), 51 (21); HRMS (ESI+): m/z: calculated for C16H16NO3 [M+H]
+: 270.11239, found: 270.11247. 
Methyl (Z)-2-(4-methoxyphenyl)-2-((4-methoxyphenyl)imino)acetate (32). Yellow solid (103 mg, 
mixture of two geometric isomers (≈85:15), 69%). The spectral data of 
the major isomer is given. M.p.: 91-92 °C; 1H NMR (400 MHz, CDCl3): δ = 
7.84–7.77 (m, 2 H), 7.00–6.91 (m, 4 H), 6.90–6.83 (m, 2 H), 3.87 (s, 3 H), 
3.80 (s, 3 H), 3.67 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 166.4, 
162.5, 158.7, 157.2, 143.6, 129.8, 127.0, 121.3, 114.3, 114.2, 55.6, 55.5, 
52.0; IR (film): 𝜈 = 3012, 2973, 2953, 2937, 2914, 2839, 1729, 1604, 1594, 1572, 1510, 1498, 1452, 
1309, 1244, 1160, 1022, 842, 510; MS (EI, %): m/z = 299 [M]+ (19), 241 (15), 240 (100), 225 (6), 197 





Methyl (Z)-4-(2-ethoxy-2-oxo-1-(phenylimino)ethyl)benzoate (34). Yellow oil (140 mg, mixture of 
two geometric isomers (96:4), 90%). The spectral data of the major isomer 
is given. 1H NMR (400 MHz, CDCl3): δ = 8.16–8.10 (m, 2 H), 7.99–7.94 (m, 
2 H), 7.36–7.30 (m, 2 H), 7.19–7.13 (m, 1 H), 6.99–6.94 (m, 2 H), 4.14 (q, 
J = 7.1 Hz, 2 H), 3.95 (s, 3 H), 0.99 (t, J = 7.1 Hz, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 166.5, 164.6, 
159.4, 150.0, 137.8, 132.9, 130.0, 129.0, 128.1, 125.4, 119.6, 61.8, 52.5, 13.8; IR (liquid): 𝜈 = 2983, 
2953, 1721, 1624, 1435, 1274, 1223, 1187, 1106, 1014, 761, 696; MS (GC-EI, %): m/z = 311 [M]+ (3), 
280 (1), 239 (13), 238 (74), 179 (6), 152 (2), 130 (3), 104 (4), 77 (100), 51 (13); HRMS (ESI+): m/z: 
calculated for C18H17NO4Na [M+Na]
+: 334.10498, found: 334.10484. 
Methyl (Z)-4-(2-ethoxy-1-((4-methoxyphenyl)imino)-2-oxoethyl)benzoate (35). Yellow solid 
(113 mg, mixture of two geometric isomers (94:6), 66%). The spectral 
data of the major isomer is given. M.p.: 75-76 °C; 1H NMR (400 MHz, 
CDCl3): δ = 8.14–8.09 (m, 2 H), 7.97–7.91 (m, 2 H), 7.01–6.95 (m, 
2 H), 6.92–6.86 (m, 2 H), 4.20 (q, J = 7.1 Hz, 2 H), 3.95 (s, 3 H), 3.81 (s, 
3 H), 1.09 (t, J = 7.1 Hz, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 
166.6, 165.4, 158.5, 157.8, 143.0, 138.2, 132.6, 130.0, 127.9, 121.4, 114.3, 61.8, 55.6, 52.5, 14.0; IR 
(film): 𝜈 = 3007, 2981, 2959, 2838, 1713, 1630, 1499, 1434, 1288, 1240, 1224, 1189, 1105, 1014, 708; 
MS (EI, %): m/z = 341 [M]+ (14), 269 (16), 268 (100), 253 (2), 225 (2), 209 (3), 166 (<1), 119 (1), 92 (4), 
77 (4); HRMS (GC-EI): m/z: calculated for C19H19NO5 [M]
+: 341.12577, found: 341.12566. 
Methyl (Z)-2-phenyl-2-((4-(prop-1-yn-1-yl)phenyl)imino)acetate (29). Orange oil (90 mg, mixture of 
two geometric isomers (93:7), 65%). The spectral data of the major isomer is 
given. 1H NMR (400 MHz, CDCl3): δ = 7.90–7.83 (m, 2 H), 7.56–7.50 (m, 1 H), 
7.50–7.43 (m, 2 H), 7.40–7.34 (m, 2 H), 6.92–6.85 (m, 2 H), 3.64 (s, 3 H), 2.06 
(s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 165.4, 160.1, 149.4, 133.8, 132.3, 
132.1, 128.9, 128.2, 120.8, 119.7, 85.8, 79.7, 52.1, 4.5; IR (liquid): 𝜈 = 3062, 
3035, 2951, 2915, 2850, 1731, 1623, 1498, 1226, 1195, 1165, 1007, 848, 688, 561; MS (GC-EI, %): m/z 
= 277 [M]+ (23), 219 (16), 218 (100), 203 (1), 140 (<1), 115 (14), 109 (1), 89 (5), 77 (1), 65 (2), 63 (2); 
HRMS (ESI+): m/z: calculated for C18H16NO2 [M+H]
+: 278.11755, found: 278.11757. 
Methyl (Z)-2-((4-azidophenyl)imino)-2-phenylacetate (30). Yellow oil (100 mg, mixture of two 
geometric isomers (93:7), 71%). The spectral data of the major isomer is given. 1H 
NMR (400 MHz, CDCl3): δ = 7.89–7.83 (m, 2 H), 7.56–7.50 (m, 1 H), 7.50–7.44 (m, 
2 H), 7.04–6.96 (m, 4 H), 3.69 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 165.6, 
160.4, 147.2, 136.9, 133.8, 132.1, 128.9, 128.1, 121.4, 119.7, 52.2; IR (liquid): 𝜈 = 
3062, 3035, 2951, 2108, 2077, 1731, 1621, 1497, 1294, 1226, 1195, 1166, 1006, 841, 688, 674, 556; 
MS (EI, %): m/z = 280 [M]+ (10), 253 (17), 252 (100), 221 (8), 208 (6),  207 (36), 194 (5), 193 (30), 192 
(19), 180 (10), 168 (3), 167 (4), 166 (5), 141 (1), 140 (3), 139 (2), 129 (1), 120 (1), 118 (3), 115 (2), 106 
S-16 
 
(9), 105 (5), 104 (4), 103 (3), 97 (2), 90 (29), 80 (21), 77 (10), 63 (12); HRMS (ESI+): m/z: calculated for 
C15H13N4O2 [M+H]
+: 281.10330, found: 281.10347. 
N-Phenyl-9H-fluoren-9-imine (37). Yellow oil (66 mg, 67%). The spectral data matched the previously 
reported values.28 1H NMR (400 MHz, CDCl3): δ = 7.90 (d, J = 7.5 Hz, 1 H), 7.60–7.52 
(m, 2 H), 7.47–7.35 (m, 3 H), 7.35–7.24 (m, 2 H), 7.23–7.14 (m, 1 H), 7.01–6.94 (m, 
2 H), 6.88 (td, J = 7.6 Hz, J = 1.0 Hz, 1 H), 6.54  (d, J = 7.7 Hz, 1 H); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 163.0, 151.9, 143.9, 142.0, 137.6, 132.0, 131.9, 131.3, 129.4, 128.5, 127.8, 
127.2, 124.1, 123.4, 120.3, 119.7, 118.4. 
Representative Procedure for the Rhodium Catalyzed Metathesis between Diazo Compounds and 
Azoarenes at Elevated Temperature. 
Octyl (Z)-4-((2-methoxy-2-oxo-1-phenylethylidene)amino)benzoate (20). A solution of diazo 
compound 6b (101.5 mg, 0.576 mmol) in toluene (2 mL) was added via syringe 
pump over the course of 2 h to a solution of dioctyl 4,4'-(diazene-1,2-diyl)(E)-
dibenzoate (122.9 mg, 0.248 mmol) and [Cp*RhI2]2 (2.2 mg, 2.2 µmol) in 
toluene (13 mL) at 90 °C under constant irradiation with the light emitted by a 
blue LED (Figure S6). After consumption of the starting material, as indicated by TLC, the mixture was 
concentrated in vacuo. The residue was purified by flash chromatography (silica, hexane/EtOAc, 20:1 
+ 1% Et3N) to give the title compound as an orange oil (175 mg, one isomer, 89%). The spectral data 
of the major isomer matched the previously reported values. 1H NMR (400 MHz, CDCl3): δ = 8.06–
8.00 (m, 2 H), 7.90–7.85 (m, 2 H), 7.58–7.51 (m, 1 H), 7.51–7.45 (m, 2 H), 7.01–6.95 (m, 2 H), 4.31 (t, 
J = 6.7 Hz), 3.63 (s, 3 H), 1.77 (quint, J = 6.8 Hz), 1.52–1.23 (m, 12 H), 0.89 (t, J = 6.9 Hz); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 166.5, 164.9, 160.6, 154.3, 133.5, 132.4, 130.7, 129.0, 128.3, 127.1, 119.4, 65.2, 
52.2, 31.9, 29.4, 29.3, 28.9, 26.2, 22.8, 14.2; IR (liquid): 𝜈 = 2953, 2926, 2855, 1736, 1713, 1598, 1269, 
1227, 1196, 1163, 1099, 1009, 861, 772, 689; MS (EI, %): m/z = 395 [M]+ (10), 337 (23), 336 (100), 266 
(6), 224 (17), 179 (7), 104 (<1), 103 (<1), 76 (2), 65 (1); HRMS (ESI+): m/z: calculated for C24H30NO4 
[M+H]+: 396.216934, found: 396.21649. 
 
Figure S6. Experimental set-up for the 
rhodium catalyzed metathesis between 
diazo compounds and azoarenes at 
elevated temperatures: two-neck Schlenk 
flask in oil bath with septum and vigreux 
column (centre), syringe pump (in green) 
with syringe in the back, self-made LED 
array (see Figure S4) wrapped in 




The following compounds were prepared analogously: 
Methyl (Z)-2-phenyl-2-((4-(trifluoromethyl)phenyl)imino)acetate (22). Orange oil (128 mg, mixture 
of two geometric isomers (94:6), 84%). The spectral data of the major isomer are 
given. 1H NMR (400 MHz, CDCl3): δ = 7.91–7.46 (m, 2 H), 7.63–7.58 (m, 2 H), 7.58–
7.53 (m, 1 H), 7.53–7.46 (m, 2 H), 7.06–7.01 (m, 2 H), 3.65 (s, 3 H); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 164.8, 161.1, 153.2, 133.4, 132.5, 129.0, 128.3, 127.0 (q, 
2J = 32.4 Hz), 126.3 (q, 3J = 3.7 Hz), 124.4 (q, 1J = 270.7 Hz), 119.8, 52.2; 19F{1H} NMR (282 MHz, CDCl3): 
δ = −62.1; IR (liquid): 𝜈 = 3065, 3054, 2955, 1735, 1608, 1319, 1230, 1163, 1063, 1015, 1009, 852, 
689; MS (GC-EI, %): m/z = 307 [M]+ (5), 288 (2), 249 (15), 248 (100), 228 (3), 208 (2), 172 (1), 145 (41), 
125 (10), 103 (10), 95 (21), 77 (29), 51 (5); HRMS (ESI+): m/z: calculated for C16H13NO2F3 [M+H]
+: 
308.08929, found: 308.08901. 
Methyl (Z)-2-((3-acetylphenyl)imino)-2-phenylacetate (28). Orange oil (116 mg, one isomer, 83%). 
1H NMR (400 MHz, CDCl3): δ = 7.90–7.85 (m, 2 H), 7.76 (ddd, J = 7.8 Hz, 
J = 1.7 Hz, J = 1.1 Hz, 1 H), 7.58–7.52 (m, 2 H), 7.52–7.46 (m, 2 H), 7.44 (t, 
J = 7.8 Hz, 1 H), 7.17 (ddd, J = 7.8 Hz, J = 2.2 Hz, J = 1.0 Hz, 1 H), 3.65 (s, 3 H), 
2.60 (s, 3 H); 13C{1H} NMR (100 MHz, CDCl3): δ = 197.8, 165.2, 161.1, 150.4, 
138.0, 133.6, 132.3, 129.4, 129.0, 128.2, 124.9, 124.3, 119.8, 52.1, 26.9; IR (liquid): 𝜈 = 3063, 3004, 
2952, 1732, 1683, 1624, 1578, 1429, 1262, 1216, 1163, 1010, 687; MS (GC-EI, %): m/z = 281 [M]+ (7), 
223 (16), 222 (100), 179 (2), 119 (5), 104 (7), 103 (5), 91 (40), 77 (21), 76 (32), 65 (12), 50 (10), 43 
(29); HRMS (ESI+): m/z: calculated for C17H16NO3 [M+H]
+: 282.11247, found: 282.11272. 
Octyl (Z)-4-((2-methoxy-1-(4-methoxyphenyl)-2-oxoethylidene)amino)benzoate (33). Orange oil 
(138 mg, one isomer, 65%). 1H NMR (400 MHz, CDCl3): δ = 8.05–
7.99 (m, 2 H), 7.86–7.79 (m, 2 H), 7.00–6.93 (m, 4 H), 4.30 (t, 
J = 6.7 Hz), 3.88 (s, 3 H), 3.61 (s, 3 H), 1.77 (quint, J = 6.9 Hz), 1.50–
1.40 (m, 2 H), 1.40–1.22 (m, 10 H), 0.89 (t, J = 6.9 Hz); 13C{1H} NMR 
(100 MHz, CDCl3): δ = 166.6, 165.1, 163.0, 159.8, 154.6, 130.7, 
130.2, 126.8, 126.2, 119.6, 114.4, 65.2, 55.6, 52.1, 31.9, 29.4, 
29.3, 28.9, 26.2, 22.8, 14.2; IR (liquid): 𝜈 = 2953, 2927, 2855, 1736, 1712, 1592, 1573, 1513, 1256, 
1229, 1158, 1112, 1098, 1017, 839, 772, 704; MS (EI, %): m/z = 425 [M]+ (3), 425 (9), 368 (4), 367 
(22), 366 (100), 296 4), 254 (14), 209 (5), 118 (1), 76 (<1); HRMS (ESI+): m/z: calculated for C25H32NO5 
[M+H]+: 426.22750, found: 426.22704. 
Methyl (Z)-4-(2-ethoxy-1-((4-((octyloxy)carbonyl)phenyl)imino)-2-oxoethyl)benzoate (36). Brown 
oil (138 mg, one isomer, 38%). 1H NMR (400 MHz, CDCl3): δ = 
8.17–8.11 (m, 2 H), 8.06–8.00 (m, 2 H), 7.99–7.94 (m, 2 H), 
7.02–6.96 (m, 2 H), 4.14 (q, J = 7.2 Hz, 2 H), 4.31 (t, J = 6.7 Hz, 
2 H), 3.96 (s, 3 H), 1.83–1.71 (m, 2 H), 1.50–1.40 (m, 2 H), 1.40–
1.22 (m, 8 H), 0.88 (t, J = 6.8 Hz, 3 H); 13C{1H} NMR (100 MHz, 
CDCl3): δ = 166.4 (2 C), 164.0, 159.9, 154.0, 137.3, 133.2, 130.7, 130.1, 128.3, 127.3, 119.3, 65.3, 62.0, 
S-18 
 
52.6, 31.9, 29.4, 29.3, 28.9, 26.2, 22.8, 14.2, 13.9; IR (liquid): 𝜈 = 2954, 2927, 2856, 1715, 1600, 1268, 
1189, 1164, 1100, 1014, 869, 772, 700; MS (EI, %): m/z = 467 [M]+ (5), 436 (2), 395 (24), 394 (100), 
338 (4), 282 (12), 237 (4), 179 (<1), 121 (<1), 76 (1); HRMS (ESI+): m/z: calculated for C27H33NO6Na 














H NMR spectra (500 MHz, CD2Cl2) of the stoichiometric (1:1) reaction of carbene complex 10c and 
(Z)-16 recorded at different temperatures. For an explanation see text below (* = residual CDHCl2 in CD2Cl2). 




An ill-defined mixture was observed at the starting point of the experiment (−50 °C, t = 0 h, Figure S7-
A). Warming this mixture to −40 °C over 45 min resulted in the slow formation of the diaziridine 
intermediate 41 (Figure S7-B). After 3 h at −40 °C the formation of 41 was complete (Figure S7-C). 41 
was stable at this temperature overnight (Figure S7-D, t = 15 h) allowing full characterization by 
NMR. Warming the sample to 25 °C resulted in conversion of 41 to imine 31 and (E)-16 (figure S7-E). 








H} NMR spectra (500 MHz, CD2Cl2) of the reaction mixture at −40 °C (t = 3 h; A), the reaction 
mixture at 25 °C (B; compare Figure S7-F), an isolated sample of imine 31 (C) and an isolated sample of (E)-16 









H NMR spectra (500 MHz, CD2Cl2) of the stoichiometric (2:1) reaction of carbene complex 10c and 
(Z)-16 at different temperatures. For an explanation see text below (* = residual CDHCl2 in CD2Cl2). Color coding 
refers to the structures in the equation at the top of the page. 
 
An ill-defined mixture was observed at the starting point of the experiment (−50 °C). Warming this 
mixture to −40 °C resulted in the slow formation of 1 equivalent of diaziridine intermediate 41 while 
1 equivalent of complex 10c remained in the solution. Increasing the temperature to ca. −25 °C 
resulted in the selective conversion of 10c and 41 to imine 31. Full conversion was reached at about 




Iridium Carbene Complex 13 
 
 






























































































Iridium Carbene Complex 14a 
 
 












































































































































Iridium Carbene Complex 14b 
 
 





















































































































































































































































































































































Rhodium Carbene Complex 12 
 
 































































































Cyclometalated Complex 4 
 
 





























































































































































































































Cyclometallated acetonitrile complex 2 
 
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Compound from table 2, entry 1 
 
 









































































































































































Compound from table 2, entry 4 
 
 














































































































































































































Compound from table 2, entry 5 
 
 























































































































































Compound from table 2, entry 6 
 
 



















































































































































































Compound from table 2, entry 7 
 
 







































































































































































































































Compound from table 2, entry 8 
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